As Polifarma, with our innovative product portfolio offering solutions in various therapeutic areas, we ensure that people around the world, have easy access to high-quality and safe medicines. We are among Türkiye's 500 largest industrial companies and maintain our leading position in the pharmaceutical sector. According to studies conducted by independent research companies, we stand out as the most recommended, most satisfying, and most trusted brand in hospital products. With our R&D investments, we are rising every year to the top ranks in the Türkiye R&D 500 list of “Companies Investing the Most in R&D, Acquiring the Most Brands, and Running the Most Projects,” both across all sectors and within the pharmaceutical sector. For nearly 40 years, we have been steadily progressing on the path of sustainable growth by focusing on quality and human health in production.

We know that the impact of our R&D investments is not limited to the health sector; it creates a wide range of effects, from social benefits to economic prosperity. We continue our investments unabated in line with our innovative solutions and our vision of easy access to medicine. As one of the most important steps in this vision, we have opened our new R&D center in Ergene, Tekirdağ, built on an area of 11,233 m². This center, one of the milestones of our goal to become a “global health hub,” is one of Turkey's most comprehensive R&D centers, bringing together API synthesis and finished product manufacturing under one roof, developing innovative solutions for rare diseases, and featuring seminar rooms, laboratories equipped with the latest technology, and production areas. Additionally, it is one of only 6 pharmaceutical companies in Türkiye with the capability and approval to synthesize Active Pharmaceutical Ingredients (API). At this center, we will contribute to improving access to healthcare by producing local SMA drugs and the active ingredient (Nusinersen), as well as drugs and APIs for various genetic diseases.